Literature DB >> 20802024

Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome.

Gudrun Göhring1, Kyra Michalova, H Berna Beverloo, David Betts, Jochen Harbott, Oskar A Haas, Gitte Kerndrup, Laura Sainati, Eva Bergstraesser, Henrik Hasle, Jan Stary, Monika Trebo, Marry M van den Heuvel-Eibrink, Marco Zecca, Elisabeth R van Wering, Alexandra Fischer, Peter Noellke, Brigitte Strahm, Franco Locatelli, Charlotte M Niemeyer, Brigitte Schlegelberger.   

Abstract

To identify cytogenetic risk factors predicting outcome in children with advanced myelodysplastic syndrome, overall survival of 192 children prospectively enrolled in European Working Group of Myelodysplastic Syndrome in Childhood studies was evaluated with regard to karyotypic complexity. Structurally complex constitutes a new definition of complex karyotype characterized by more than or equal to 3 chromosomal aberrations, including at least one structural aberration. Five-year overall survival in patients with more than or equal to 3 clonal aberrations, which were not structurally complex, did not differ from that observed in patients with normal karyotype. Cox regression analysis revealed the presence of a monosomal and structurally complex karyotype to be strongly associated with poor prognosis (hazard ratio = 4.6, P < .01). Notably, a structurally complex karyotype without a monosomy was associated with a very short 2-year overall survival probability of only 14% (hazard ratio = 14.5; P < .01). The presence of a structurally complex karyotype was the strongest independent prognostic marker predicting poor outcome in children with advanced myelodysplastic syndrome.

Entities:  

Mesh:

Year:  2010        PMID: 20802024     DOI: 10.1182/blood-2010-04-280313

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Cytogenetics and clinical features of pediatric myelodysplastic syndrome in Japan.

Authors:  Koichi Moriwaki; Atsushi Manabe; Takeshi Taketani; Akira Kikuchi; Tatsutoshi Nakahata; Yasuhide Hayashi
Journal:  Int J Hematol       Date:  2014-09-27       Impact factor: 2.490

Review 2.  Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia.

Authors:  Yahya Daneshbod; Leila Kohan; Vahideh Taghadosi; Olga K Weinberg; Daniel A Arber
Journal:  Curr Treat Options Oncol       Date:  2019-02-11

3.  Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study.

Authors:  Eva A Coenen; Susana C Raimondi; Jochen Harbott; Martin Zimmermann; Todd A Alonzo; Anne Auvrignon; H Berna Beverloo; Myron Chang; Ursula Creutzig; Michael N Dworzak; Erik Forestier; Brenda Gibson; Henrik Hasle; Christine J Harrison; Nyla A Heerema; Gertjan J L Kaspers; Anna Leszl; Nathalia Litvinko; Luca Lo Nigro; Akira Morimoto; Christine Perot; Dirk Reinhardt; Jeffrey E Rubnitz; Franklin O Smith; Jan Stary; Irina Stasevich; Sabine Strehl; Takashi Taga; Daisuke Tomizawa; David Webb; Zuzana Zemanova; Rob Pieters; C Michel Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Blood       Date:  2011-05-06       Impact factor: 22.113

Review 4.  Myelodysplastic and myeloproliferative disorders of childhood.

Authors:  Henrik Hasle
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 5.  Heterogeneity of GATA2-related myeloid neoplasms.

Authors:  Shinsuke Hirabayashi; Marcin W Wlodarski; Emilia Kozyra; Charlotte M Niemeyer
Journal:  Int J Hematol       Date:  2017-06-22       Impact factor: 2.490

6.  Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.

Authors:  Heesun J Rogers; James W Vardiman; John Anastasi; Gordana Raca; Natasha M Savage; Athena M Cherry; Daniel Arber; Erika Moore; Jennifer J D Morrissette; Adam Bagg; Yen-Chun Liu; Susan Mathew; Attilio Orazi; Pei Lin; Sa A Wang; Carlos E Bueso-Ramos; Kathryn Foucar; Robert P Hasserjian; Ramon V Tiu; Matthew Karafa; Eric D Hsi
Journal:  Haematologica       Date:  2014-01-24       Impact factor: 9.941

7.  Myelodysplastic syndromes in children: where are we today?

Authors:  A T K Rau; A K Shreedhara; S Kumar
Journal:  Ochsner J       Date:  2012

8.  Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation.

Authors:  Nicolas Waespe; Machiel Van Den Akker; Robert J Klaassen; Lani Lieberman; Meredith S Irwin; Salah S Ali; Mohamed Abdelhaleem; Bozana Zlateska; Mira Liebman; Michaela Cada; Tal Schechter; Yigal Dror
Journal:  Haematologica       Date:  2016-08-18       Impact factor: 9.941

9.  Shared Copy Number Variation in Simultaneous Nephroblastoma and Neuroblastoma due to Fanconi Anemia.

Authors:  A Serra; K Eirich; A K Winkler; K Mrasek; G Göhring; G Barbi; H Cario; B Schlegelberger; B Pokora; T Liehr; C Leriche; D Henne-Bruns; T F Barth; D Schindler
Journal:  Mol Syndromol       Date:  2012-08-23

10.  Array-CGH as an adjuvant tool in cytogenetic diagnosis of pediatric MDS and JMML.

Authors:  Amanda Gonçalves Silva; Mariana Maschietto; Daniel Onofre Vidal; Leandro Mota Peliçario; Elvira Deolinda Rodrigues Pereira Velloso; Luiz Fernando Lopes; Ana Cristina Krepischi; Carla Rosenberg
Journal:  Med Oncol       Date:  2013-10-02       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.